All In Biotech

Drug Trial Radar · NCT07937657

A Study to Evaluate the Safety and Pain Relief of MAX-001 After Surgical Removal of Wisdom Teeth

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof-of-Concept Study to Evaluate the Safety and Analgesic Efficacy of MAX-001 in Participants Undergoing Extraction of Bilateral Impacted Mandibular Third Molar Teeth

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

276

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Maxona Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of MAX-001 in participants with post-operative dental pain after wisdom teeth removal.

Conditions

  • Impacted Third Molar Tooth
  • Tooth Extraction Status Nos

Interventions

  • MAX-001Drug

    30 mg oral tablets

  • PlaceboDrug

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summed Pain Intensity Difference 12 hours (SPID12) vs placebo using the Numerical Pain Rating Scale (NPRS) for painTime frame: 12 hours
  2. Incidence of Treatment Emergent Adverse Events (TEAEs) as assessed by patient response to questions and spontaneous reporting of TEAEsTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CenExel JBR

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.